COPD ExacerbationEmoDNCT07351929
Emotional-distress-based Integrated Care Programme in Patients With an Acute Exacerbation of COPD
A study testing EmoD Intervention in people with COPD Exacerbation, run by University of Zurich at 1 site in Switzerland.
Trial summary
The investigators have developed a new counseling service that focuses on the emotional distress experienced by people living with COPD. The service has been specially developed for patients who have experienced a deterioration in their lung condition (known as an acute exacerbation of COPD). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COPD Exacerbation
- What is being tested?
- EmoD Intervention
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteSwitzerland
- Study dates
- 12 Jan 2026to 10 Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with a confirmed diagnosis of COPD (GOLD 1-4)
- Hospitalisation due to a COPD exacerbation and decision to start with steroids and/or antibiotics (severe exacerbation)
- Age ≥ 18
- Inpatient on the pneumology or medical ward
Who cannot join
- Cognitive impairment (dementia, delirium) (DOS>3 or AES>6 or Mini-Cog<3)
- Unstable psychiatric disorders
- Not speaking German
- Lung transplant
- Pneumonia caused by chronic colonization by bacteria (Legionella, nontuberculous mycobacteria (NTM))
- Unable to telephone
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
University Hospital Zürich
Zurich, Canton of Zurich, 8091
About this study
Official title: An Emotional-distress-based Integrated Care Programme in Patients With an Acute Exacerbation of COPD (EmoD) - A Feasibility Study
The investigators have developed a new counseling service that focuses on the emotional distress experienced by people living with COPD. The service has been specially developed for patients who have experienced a deterioration in their lung condition (known as an acute exacerbation of COPD). The new program is led by an APN team. Other professionals are involved in the program, such as medical staff and physiotherapists. The new counseling service lasts three months. Patients will receive ten counseling sessions with a specialized nurse.
The overall objective of the study is to assess the feasibility of the newly developed emotional-distress-based integrated care programme.
- Conditions
- COPD Exacerbation
- Being tested
- EmoD Intervention
- Keywords
- COPD, Feasibility study, Mixed-methods design, Emotional distress, Integrated care programme, APN
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EmoD InterventionOther
Patients who are hospitalised due to a COPD exacerbation will be aligned to a nurse-led emotional-distress-based integrated care programme for three months.
| Study group | Role | What they receive |
|---|---|---|
| Intervention Group | Experimental | Not described Receives: Other: EmoD Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in COPD-related emotional distress (CRED)
Change in COPD-related emotional distress between baseline and month 3. COPD-related emotional distress will be assessed using the newly developed 'COPD-Related Emotional Distress Questionnaire (CRED)', which was developed for CF and COPD patients (publication in progress; former name of the questionnaire: IRED-RESP). The questionnaire includes 36 items and assesses distress related to symptoms, treatment, restrictions in range of mobility and participation in social life, unpredictability of the disease, and stigma, using a 5-point Likert scale. Higher scores mean more emotional distress (worse outcome).
Measured: Quantitative data will be collected baseline, in the first month after hospitalization due to AECPOD (MZP 1, week 0-4), and follow-up, three months after (MZP2, week 14-17)
Secondary outcomes (28)
Reach: Total number of patients who take up the programme
Number of patients who accept the study and / or intervention is documented by the study team.
Measured: Four months
Reach: Percentage of patients who take part in at least one outpatient intervention
Number of interventions per patient and number of patients with termination of the programme before Week 13 is documented by the ANP team
Measured: Four months
Reach: Reasons for participating in the programme (facilitators and barriers)
Patients who decline the intervention are asked by the ANP team and/or the study nurse for their reasons (barriers). The reasons for taking up the programme (facilitators) will be qualitatively investigated in interviews. A semi-structured interview guide will be used.
Measured: Four months
Reach: Reasons for ending (prematurely or on schedule) the programme (facilitators and barriers)
The reasons for ending (prematurely or on schedule) the programme will be qualitatively investigated in interviews. A semi-structured interview guide will be used.
Measured: Four months
Potential effectiveness: Change in depression
Quantitative Depression will be screened with the Hospital Anxiety and Depression Scale (HADS). The concept is measured with seven 4-point rating scales ranging from 0 to 3. The sum score ranging from 0 to 21 will be calculated (Zigmond \& Snaith, 1983). Higher scores meaning worse outcomes. Differences between MZP1 and MZP2 will be calculated per subscore.
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in anxiety
Quantitative Anxiety will be screened with the Hospital Anxiety and Depression Scale (HADS). The concept is measured with seven 4-point rating scales ranging from 0 to 3. The sum score ranging from 0 to 21 will be calculated (Zigmond \& Snaith, 1983). Higher scores meaning worse outcomes. Differences between MZP1 and MZP2 will be calculated per subscore.
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health-related quality of life (QoL)
Quantitative Health-related quality of life will be assessed with the Chronic Respiratory Questionnaire (CRQ) (Guyatt et al., 1987) following the defined procedure of the developers. The self-administered questionnaire version with standardised dyspnea questions (SAS) will be used. The questionnaire was developed for patients with chronic airflow limitations and comprises 20 items which assess four domains: 1) dyspnea, 2) fatigue, 3) emotional function and 4) mastery. The scoring scale ranges from 1 (extreme) to 7 (not at all) and will be assessed with a recall period of the past two weeks. A subscore for each domain (sum of items / number of items) will be calculated. The CRQ-SAS is available in German. It has demonstrated high sensitivity in the evaluation of a rehabilitation programme (Puhan et al., 2007). Differences between MZP1 and MZP2 will be calculated per subscore.
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Patient satisfaction with programme
Quantitative The questionnaire on the quality of nursing care counseling (ANP-BQ) is used to assess patient satisfaction. This instrument includes, for example, a question to assess the satisfaction of care provided by the ANP on an NRS 1-10 (Petry et al., 2014; Weilenmann et al., 2021).
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Number of moderate exacerbations within 3 months
Quantitative The number of moderate exacerbations during the previous three months are assessed at week 14-17. For this purpose, moderate exacerbations are defined as an acute (more than normal day-to-day variation) worsening of respiratory symptoms (breathlessness, sputum and / or coughing) that are treated with systemic antibiotics and / or corticosteroids (systemic = oral or intravenous) (Global Initiative for Chronic Obstructive Lung Disease, 2019).
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Number of severe exacerbations within 3 months
Quantitative The number of severe exacerbations during the previous three months are assessed at week 14-17. For this purpose, severe exacerbations are defined as acute (more than normal day-to-day variation) worsening of respiratory symptoms (breathlessness, sputum and / or coughing) that result in hospitalisation or emergency room visit (Global Initiative for Chronic Obstructive Lung Disease, 2019).
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Rehospitalisation at day 90
Quantitative The number of COPD-related rehospitalisations after 3 months is assessed by medical chart review.
Qualitative In the case of rehospitalisation, a one-to-one interview and medical chart review will be performed to assess reasons for rehospitalisation.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Time until first rehospitalisation
Quantitative The time until first rehospitalisation is assessed by medical chart review.
Qualitative In the case of rehospitalisation, a one-to-one interview and medical chart review will be performed to assess reasons for rehospitalisation.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour smoking- current status
Quantitative Smoking behaviour will be assessed by using the questionnaire from the WHO (Global Adult Tobacco Survey Collaborative Group, 2011). It assesses the current status of smoking (yes / no).
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour smoking - ex- smoker
Quantitative Smoking behaviour will be assessed by using the questionnaire from the WHO (Global Adult Tobacco Survey Collaborative Group, 2011). If an ex-smoker, it assesses date of smoking cessation (year).
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour smoking -smoker
Quantitative Smoking behaviour will be assessed by using the questionnaire from the WHO (Global Adult Tobacco Survey Collaborative Group, 2011). If a smoker, it assesses the substance and the number per day.
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour nutrition - body weight
Quantitative Current body weight (kg) will be assessed.
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour nutrition - body height
Quantitative Current body height (m) will be assessed.
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour nutrition - BMI
Quantitative Current Body Mass Index (BMI) will be calculated according to the WHO recommendations (World Health Organization, 2000) (kg/m^2).
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour nutrition - NRS
Quantitative Current Nutritional Risk Screening (NRS) will be assessed during hospitalisation (Kondrup et al., 2003). 3 and more points meaning worse outcome.
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour physical activity - C-PPAC
Quantitative Self-report by patient based on the first two items of the clinical version of PROactive Physical Activity in COPD instrument (C-PPAC). The items measure the amount of activity over the last 7 days with a range from 0-4. Higher scores meaning better outcomes.
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour physical activity - PR
Quantitative The use of pulmonary rehabilitation/outpatient physiotherapy is recorded.
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour inhalation adherence
Quantitative Adherence to inhalation will be assessed. The items were derived from the Zurich Assessment of Therapy Adherence CF (ZATA-CF) and adapted slightly. Patients are asked how often they needed to inhale the medication per day and how often they had skipped an inhalation in the past seven days. Higher scores meaning worse outcomes.
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour action plan
Quantitative Availability of a prescription for an action plan (with/without self-medication) and adherence of patient to the action plan will be assessed.
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour oxygen use
Quantitative Availability of an oxygen prescription and the patient's compliance with the prescription are assessed.
Qualitative A semi-structured interview guide will be used based on the quantitative results.
Measured: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Implementation: Percent of programme components carried out according to the intervention manual
Quantitative Completed intervention components per patient were documented by the ANP team. Necessary but not or not fully completed parts of the intervention are also documented.
Qualitative To understand reasons for performing, omitting or modifying components of the programme structured small group interviews will be conducted with HCP's involved in intervention delivery. The interview guide will be based on the results of the document analysis.
Measured: Data will be collected at the earliest six months after the start of the programme
Implementation: Acceptability of the programme
Quantitative The German translations of the Acceptability of Intervention Measure (AIM) scale will be used to assess the healthcare professional's perspective. The scale contains four items; all are rated on a 5-point response scale (1 = completely disagree, 5 = completely agree), we added a sixth option "no response" (0 points).
Qualitative To understand reasons for the results structured small group interviews will be conducted with involved HCPs. The interview guide will be based on the results of the questionnaires.
Measured: Data will be collected at the earliest six months after the start of the programme
Implementation: Appropriateness of the programme
Quantitative The German translations of the Intervention Appropriateness Measure (IAM) scale will be used to assess the healthcare professional's perspective. The scale contains four items; all are rated on a 5-point response scale (1 = completely disagree, 5 = completely agree), we added a sixth option "no response" (0 points).
Qualitative To understand reasons for the results structured small group interviews will be conducted with involved HCPs. The interview guide will be based on the results of the questionnaires.
Measured: Data will be collected at the earliest six months after the start of the programme
Implementation: Feasibility of the programme
Quantitative The German translations of the Feasibility of Intervention Measure (FIM) scale will be used to assess the healthcare professional's perspective. The scale contains four items; all are rated on a 5-point response scale (1 = completely disagree, 5 = completely agree), we added a sixth option "no response" (0 points).
Qualitative To understand reasons for the results structured small group interviews will be conducted with involved HCPs. The interview guide will be based on the results of the questionnaires.
Measured: Data will be collected at the earliest six months after the start of the programme
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jan 2026
- Study start12 Jan 2026
- Primary completion10 Sep 2026 (estimated)
- Study completion10 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COPD ExacerbationStudies of the same condition, open and under way.
- More trials run by University of ZurichThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Explanatory sequential mixed-methods design
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Zurich
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07351929
- Sponsor's protocol ID
- 2025-01178
- Other IDs
- 2025
- Acronym
- EmoD
- Status last verified
- Jun 2026
- First submitted
- 14 Nov 2025
- Last updated
- 16 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Emotional-distress-based Integrated Care Programme in Patients With an Acute Exacerbation of COPD (EmoD) - A Feasibility Study
- ClinicalTrials.gov ID
- NCT07351929
- Acronym / sponsor ID
- EmoD / 2025-01178
- Conditions
- COPD Exacerbation
- Keywords
- COPD, Feasibility study, Mixed-methods design, Emotional distress, Integrated care programme, APN
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- University of ZurichUniversity, hospital or other
- Study start
- 12 Jan 2026 (actual)
- Primary completion
- 10 Sep 2026 (estimated)
- Study completion
- 10 Sep 2026 (estimated)
- First posted
- 20 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators have developed a new counseling service that focuses on the emotional distress experienced by people living with COPD. The service has been specially developed for patients who have experienced a deterioration in their lung condition (known as an acute exacerbation of COPD). The new program is led by an APN team. Other professionals are involved in the program, such as medical staff and physiotherapists. The new counseling service lasts three months. Patients will receive ten counseling sessions with a specialized nurse.
The overall objective of the study is to assess the feasibility of the newly developed emotional-distress-based integrated care programme.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Explanatory sequential mixed-methods design
| Arm | Type | Receives |
|---|---|---|
| Intervention Group | Experimental | Other: EmoD Intervention |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients with a confirmed diagnosis of COPD (GOLD 1-4)
- Hospitalisation due to a COPD exacerbation and decision to start with steroids and/or antibiotics (severe exacerbation)
- Age ≥ 18
- Inpatient on the pneumology or medical ward
Key exclusion criteria (6 listed)
- Cognitive impairment (dementia, delirium) (DOS>3 or AES>6 or Mini-Cog<3)
- Unstable psychiatric disorders
- Not speaking German
- Lung transplant
- Pneumonia caused by chronic colonization by bacteria (Legionella, nontuberculous mycobacteria (NTM))
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EmoD InterventionPatients who are hospitalised due to a COPD exacerbation will be aligned to a nurse-led emotional-distress-based integrated care programme for three months. | Other | Intervention Group |
Primary outcome
Change in COPD-related emotional distress (CRED)
Time frame: Quantitative data will be collected baseline, in the first month after hospitalization due to AECPOD (MZP 1, week 0-4), and follow-up, three months after (MZP2, week 14-17)
Change in COPD-related emotional distress between baseline and month 3. COPD-related emotional distress will be assessed using the newly developed 'COPD-Related Emotional Distress Questionnaire (CRED)', which was developed for CF and COPD patients (publication in progress; former name of the questionnaire: IRED-RESP). The questionnaire includes 36 items and assesses distress related to symptoms, treatment, restrictions in range of mobility and participation in social life, unpredictability of the disease, and stigma, using a 5-point Likert scale. Higher scores mean more emotional distress (worse outcome).
28 secondary outcomes
Reach: Total number of patients who take up the programme
Time frame: Four months
Reach: Percentage of patients who take part in at least one outpatient intervention
Time frame: Four months
Reach: Reasons for participating in the programme (facilitators and barriers)
Time frame: Four months
Reach: Reasons for ending (prematurely or on schedule) the programme (facilitators and barriers)
Time frame: Four months
Potential effectiveness: Change in depression
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in anxiety
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health-related quality of life (QoL)
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Patient satisfaction with programme
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Number of moderate exacerbations within 3 months
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Number of severe exacerbations within 3 months
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Rehospitalisation at day 90
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Time until first rehospitalisation
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour smoking- current status
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour smoking - ex- smoker
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour smoking -smoker
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour nutrition - body weight
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour nutrition - body height
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour nutrition - BMI
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour nutrition - NRS
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour physical activity - C-PPAC
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour physical activity - PR
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour inhalation adherence
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour action plan
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Potential effectiveness: Change in health behaviour oxygen use
Time frame: Study duration per patient is three months with two measurement points. Baseline measurement (MZP1) will be applied in the first month after hospitalization due to AECPOD (week 0-4). Second measurement (MZP 2) will take place in month four (week 14-17).
Implementation: Percent of programme components carried out according to the intervention manual
Time frame: Data will be collected at the earliest six months after the start of the programme
Implementation: Acceptability of the programme
Time frame: Data will be collected at the earliest six months after the start of the programme
Implementation: Appropriateness of the programme
Time frame: Data will be collected at the earliest six months after the start of the programme
Implementation: Feasibility of the programme
Time frame: Data will be collected at the earliest six months after the start of the programme
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for COPD Exacerbation
Active, not recruiting
Influence of FreeO2 on Percentage of Time Within Oxygen Saturation Target Using Noninvasive Ventilation (NIV) and Continuous Positive Airway Pressure (CPAP) for Patients Admitted for AECOPD or Bariatric Surgery
COPD Exacerbation, Oxygen Toxicity
Active, not recruiting
FreeDom: Innovative Strategy for the Management of COPD Exacerbations
Oxygen Deficiency, COPD Exacerbation
RecruitingPhase 2
Rademikibart IV for Acute Asthma and COPD Exacerbation
Asthma Acute, COPD Exacerbation Acute
Not yet recruitingPhase 1
Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations
Chronic Obstructive Pulmonary Disease (COPD)
RecruitingObservational study
Swiss Chronic Obstructive Pulmonary Disease (COPD) Management Cohort
Chronic Obstructive Pulmonary Disease, COPD Exacerbation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing EmoD Intervention in people with COPD Exacerbation, run by University of Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 16 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in COPD-related emotional distress (CRED) (time frame: Quantitative data will be collected baseline, in the first month after hospitalization due to AECPOD (MZP 1, week 0-4), and follow-up, three months after (MZP2, week 14-17)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jun 2026.